申请人:Georg-August-Universität Göttingen Stiftung
Öffentlichen Rechts, Universitätsmedizin
公开号:EP4279074A1
公开(公告)日:2023-11-22
The present invention relates to an azolo compound of Formula I
for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFβ-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.
本发明涉及一种式 I 的偶氮化合物
其中,该唑基化合物可使 TGFβ 激活的成纤维细胞的胶原蛋白 I mRNA 水平恢复正常,并将胶原蛋白的产生逆转至未受刺激的成纤维细胞的正常水平。